Profile | GDS2987 / GI_40795668-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 8.1 | 29 |
GSM215244 | HMVEC_vehicle_rep2 | 27.8 | 56 |
GSM215253 | HMVEC_vehicle_rep3 | 17.8 | 50 |
GSM215254 | HMVEC_atorvastatin_rep1 | 16.1 | 40 |
GSM215282 | HMVEC_atorvastatin_rep3 | 14.6 | 33 |
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 16.2 | 31 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 12.8 | 26 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 6.3 | 11 |
GSM215294 | HMVEC_SLx2119_rep1 | 6.3 | 23 |
GSM215295 | HMVEC_SLx2119_rep2 | 39.4 | 59 |
GSM215296 | HMVEC_SLx2119_rep3 | 17.5 | 29 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 51.4 | 60 |
GSM215310 | PASMC_vehicle_rep3 | 15.5 | 25 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 11.1 | 18 |
GSM215313 | PASMC_atorvastatin_rep3 | 44.4 | 54 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 70.2 | 69 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 11.4 | 23 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 68.4 | 69 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 35.9 | 54 |
GSM215329 | PASMC_SLx2119_rep3 | 23.9 | 42 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 25.5 | 55 |
GSM215332 | Fibroblasts_vehicle_rep3 | 23.8 | 57 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 8.8 | 24 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 10.7 | 29 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 11.2 | 28 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 25.5 | 59 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 19.7 | 52 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 30.5 | 60 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 7.4 | 22 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 6.4 | 18 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 9.7 | 25 |